Teva says vaccine makers have not taken its offer to help produce jabs | Financial Times
UBS raises Teva price target - Globes
Teva Becomes First Pharmaceutical Company to Execute Sustainability-Linked Bond Tied to Both Climate and Access to Medicine Targets
Teva boosted as FDA delays generic Copaxone - Globes
Teva, AbbVie finalize $6.6 billion U.S. opioid settlements | Reuters
Teva jumps after Wall Street upgrades, analysts say stock 'too cheap to ignore'
Teva started at neutral at UBS on pricing and legal concerns (NYSE:TEVA) | Seeking Alpha
Teva Pharmaceuticals is found liable in the opioid crisis : NPR
UBS raises Teva price target - Globes
Teva stock drops on guidance, manufacturing problems - MarketWatch
Teva stock downgraded to neutral by UBS on heels of $85 million opioid settlement - MarketWatch
Jennifer Bryan - Head of Commercial Training & Development - Teva Pharmaceuticals | LinkedIn
UBS cuts estimate of Teva's opioid liability - Globes
Teva in Talks to Buy Allergan's Generic-Drug Unit - WSJ
Teva stock downgraded to neutral by UBS on heels of $85 million opioid settlement - MarketWatch
Teva Pharmaceutical Industries Stock Jumps on a Rare Bullish View | Barron's
Investors question green tint of Teva's $5bn sustainability bond | Financial Times
Teva Pharmaceuticals Could Face Billions in Damages From Opioid Lawsuits | Barron's
Teva reaches proposed $4.35 bln settlement of U.S. opioid lawsuits | Reuters
Teva Plummets on Downgrade Following $85M Opioid Settlement - TheStreet
Teva Prepared to Fight Charges in Generics Probe If Talks Fail - Bloomberg
Teva hires ex-Novartis executive to succeed CEO Schultz | Reuters
Summer of Teva: The Mom Comfort Sandal
$4.4 Billion Opioid Settlement Gives Teva Stock a Boost | Barron's
Generic Drug Lawsuit Could Mean Big Fines for Teva, Mylan: UBS
Rebounding Teva is 'too cheap to ignore,' upbeat analysts say | Fierce Pharma
